CytomX Therapeutics (CTMX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$682.4 million.
- CytomX Therapeutics' Retained Earnings rose 394.37% to -$682.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$682.4 million, marking a year-over-year increase of 394.37%. This contributed to the annual value of -$691.6 million for FY2024, which is 440.52% up from last year.
- Latest data reveals that CytomX Therapeutics reported Retained Earnings of -$682.4 million as of Q3 2025, which was up 394.37% from -$668.2 million recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Retained Earnings registered a high of -$531.0 million during Q1 2021, and its lowest value of -$727.3 million during Q2 2023.
- Moreover, its 5-year median value for Retained Earnings was -$691.6 million (2024), whereas its average is -$675.1 million.
- As far as peak fluctuations go, CytomX Therapeutics' Retained Earnings tumbled by 3521.34% in 2021, and later surged by 669.97% in 2025.
- Over the past 5 years, CytomX Therapeutics' Retained Earnings (Quarter) stood at -$623.6 million in 2021, then dropped by 15.93% to -$722.9 million in 2022, then fell by 0.08% to -$723.4 million in 2023, then rose by 4.41% to -$691.6 million in 2024, then rose by 1.32% to -$682.4 million in 2025.
- Its Retained Earnings was -$682.4 million in Q3 2025, compared to -$668.2 million in Q2 2025 and -$668.1 million in Q1 2025.